Clinical Trial Update: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) [Phase 2]

View source ↗

Summary

Phase 2 trial SARC029 evaluating trametinib plus pazopanib in Gastrointestinal Stromal Tumor has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Pazopanib (Pazopanib)
• Trametinib (trametinib)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: WITHDRAWN